Deal of the Day — limited-time pharmacy picks!
Retevmo 80mg Capsule

Retevmo 80mg Capsule

Prescription requiredRx Required

Salt Composition: Selpercatinib

Expiry Date: 01/2028

Special offer

Price on Request

Price on Request

Inclusive of all taxes

▼

120 capsule

About The Product

Lung Cancer, Thyroid Cancer

Selpercatinib 80mg Capsule is used to treat certain types of cancer (such as lung cancer, thyroid cancer, medullary thyroid cancer, and certain other solid tumors). ​

Description

Retevmo 80mg capsule is a prescription based anticancer medication. The medication active ingredient is Selpercatinib which belongs to the drug class of tyrosine kinase inhibitor.

It blocking abnormal RET proteins that promote the growth and spread of cancer cells, helping to slow down or stop tumor progression. The medication is used to treat RET positive non small cell lung cancer (NSCLC), Medullary thyroid cancer and other RET driven tumors.

Taking the dose exactly as prescribed by the healthcare professional.

Uses

  • Treats non small cell lung cancer, thyroid cancer and certain other solid tumors.

Side Effects

  • Every medication has several side effects.
  • Retevmo 80mg capsule also causes various symptoms, many of them are resolve on their own and some need proper medical attention.
  • Common ones include: • Swelling • Diarrhea • Fatigue • Dryness • Fever • Abdominal pain • Dizziness • Weakness​

How To Use

  • Dosage and duration is correctly administered by the healthcare professional to ensure the medication is effective and lower the risk of side effects on patients. Retevmo 80mg capsule should be taken with or without food at the fixed time everyday to enhance the effectiveness of the treatment.
  • Do not miss or skip the dose without consultation with a healthcare professional as it may reduce the benefit of the treatment and allow the cancer to progress or become less responsive to the therapy.

How It Works

  • Retevmo 80mg capsule works by blocking the RET ( rearranged during transfection) tyrosine kinase, which is abnormality activated in certain cancers due to RET gene fusion or mutation. By inhibiting RET growth signaling Retevmo 80mg slows or stop the growth of cancer cells in the body.
  • The medicine also prevents the body from multiplication or spreading tumor to the other body parts.

Safety Advice

Alcohol
Alcohol is prohibited while taking Retevmo 80mg capsule as it cause unwanted side effects and cause complications during the treatment.
Pregnancy
Pregnant women should avoid using Retevmo 80mg capsule as the medicine can cause harm to the baby.
Breast Feeding
Women are taking Retevmo 80mg capsule should avoid feeding milk to their baby, as it affects on breast milk and may cause serious risk to the baby.
Driving
Retevmo 80mg capsule may decrease alertness and affect the vision make you feel sleepy and dizzy but it is better to consult the doctor first.
Kidney
Retevmo 80mg capsule is not recommended to kidney patients as body may not handle the drug effectively.
Liver
Patient with liver disease must recommended the correct dose of Retevmo 80mg capsule, the medication should affect liver function and improper dosing may lead to severe liver related complications.

FAQs

Retevmo 80mg capsule can be taken by the patient of thyroid cancer, non-smalll cell lung cancer and other certain cancer.

It works by blocking the enzyme causing cancer cells and preventing the body from further growing cancer in the body.

References

• Markham, A. (2020).

Selpercatinib: first approval. Drugs, 80(11), 1119-1124. https://pubmed.ncbi.nlm.nih.gov/32557397/ • Drilon, A., Oxnard, G.

R., Tan, D. S., Loong, H.

H., Johnson, M., Gainor, J., ... & Subbiah, V. (2020).

Efficacy of selpercatinib in RET fusion–positive non–small-cell lung cancer. New England Journal of Medicine, 383(9), 813-824. https://pubmed.ncbi.nlm.nih.gov/32846060/ • Bradford, D., Larkins, E., Mushti, S.

L., Rodriguez, L., Skinner, A. M., Helms, W.

S., ... & Singh, H. (2021).

FDA approval summary: selpercatinib for the treatment of lung and thyroid cancers with RET gene mutations or fusions. Clinical Cancer Research, 27(8), 2130-2135. https://pubmed.ncbi.nlm.nih.gov/33239432/ • Zhou, C., Solomon, B., Loong, H.

H., Park, K., Pérol, M., Arriola, E., ... & Goto, K. (2023).

First-line selpercatinib or chemotherapy and pembrolizumab in RET fusion–positive NSCLC. New England Journal of Medicine, 389(20), 1839-1850. https://pubmed.ncbi.nlm.nih.gov/37870973/ • Drilon, A., Subbiah, V., Gautschi, O., Tomasini, P., De Braud, F., Solomon, B.

J., ... & Besse, B. (2023).

Selpercatinib in patients with RET fusion–positive non–small-cell lung cancer: updated safety and efficacy from the registrational LIBRETTO-001 phase I/II trial. Journal of Clinical Oncology, 41(2), 385-394. https://pubmed.ncbi.nlm.nih.gov/36122315/​

i
Trust & safety

Medical Disclaimer

Accurate, reviewed information to support informed healthcare decisions

For informational purposes only
Not a substitute for professional medical advice
Consult your doctor for diagnosis and treatment

Magicine's primary objective is to ensure that its customers receive accurate, genuine, and trustworthy information reviewed by medical experts.

The content on this website has been produced solely for informational purposes. This is not intended to take the place of medical advice and care provided by a licensed professional, though.

This information may not include all potential side effects, warnings, and details about specific lab tests, medications, and medical conditions. Please ask your doctor any questions you may have about any drug or disease.

Our goal is not to replace or substitute for the doctor-patient relationship, but to uphold and strengthen it.

Always follow advice from your doctor, pharmacist, or other licensed healthcare professional before starting, stopping, or changing any medicine or treatment.
Read full medical disclaimer in Terms & Conditions
Magicine PharmacopyCopyright 2026